Impact of Systemic Parameters Before Commencing Anti-vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema - Pan-Indian Survey of Retina Specialists

Overview

Journal Indian J Ophthalmol

Specialty Ophthalmology

Date 2021 Oct 28

PMID 34708786

Authors

P Mahesh Shanmugam

Payal Shah

Rajesh Ramanjulu

Divyansh Mishra

Affiliations

Soon will be listed here.

Abstract

Purpose: Intravitreal anti-vascular endothelial growth factor (VEGF) injection therapy has emerged as the mainstay of treatment in the management of diabetic macular edema (DME) today. Various systemic risk factors have to be considered before initiating anti-VEGF therapy. The aim of our study was to form a consensus on various systemic factors to consider before starting anti-VEGF therapy for DME.

Methods: A questionnaire was created and sent across to various retina specialists across India. A Google form with various questions pertaining to what systemic parameters would one consider before giving anti-VEGF therapy for DME was sent to each of them by email/WhatsApp/direct telephonic interview.

Results: Of the 650 retina specialists contacted, 322 responded to the questionnaire. There was no difference in responses between private and institutional practitioners. The majority would consider RBS (85%), HbA1c (61%), blood pressure (63%), and renal function (57%) as a routine before administering the anti-VEGF injection, while the majority would not consider hemoglobin (63%) or lipid profile (55%) of the patient as a routine practice prior to administering the injection.

Conclusion: In our study, most VR specialists prefer to consider RBS, HbA1c, BP, and renal profile (creatinine) routinely prior to anti-VEGF injection. We suggest that it is important to consider blood pressure control, glycemic control, HbA1c, Hb, lipid profile, and renal profile (UACR, eGFR, and creatinine) prior to anti-VEGF therapy in all diabetic patients and to discuss the need for statins in patients with dyslipidemias with the physician.

References

Chung Y, Park S, Choi S, Kim S, Moon K, Kim J . Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovasc Diabetol. 2017; 16(1):4. PMC: 5219811. DOI: 10.1186/s12933-016-0486-2. View

Singh R, Abhiramamurthy V, Gupta V, Gupta A, Bhansali A . Effect of multifactorial intervention on diabetic macular edema. Diabetes Care. 2006; 29(2):463-4. DOI: 10.2337/diacare.29.02.06.dc05-1931. View

Das T, Aurora A, Chhablani J, Giridhar A, Kumar A, Raman R . Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines. Indian J Ophthalmol. 2016; 64(1):14-25. PMC: 4821115. DOI: 10.4103/0301-4738.178142. View

Sundar D, Das T, Chhablani J, Kumar A, Sharma N . All India Ophthalmological Society members' survey: Practice pattern of intravitreal anti-vascular endothelial growth factor injection. Indian J Ophthalmol. 2020; 68(6):1095-1098. PMC: 7508122. DOI: 10.4103/ijo.IJO_1602_19. View

Aiello L, Cahill M, Wong J . Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol. 2001; 132(5):760-76. DOI: 10.1016/s0002-9394(01)01124-2. View

Ranil P, Raman R, Rachepalli S, Pal S, Kulothungan V, Lakshmipathy P . Anemia and diabetic retinopathy in type 2 diabetes mellitus. J Assoc Physicians India. 2010; 58:91-4. View

Gupta A, Raman R, Kulothungan V, Sharma T . Association of systemic and ocular risk factors with neurosensory retinal detachment in diabetic macular edema: a case-control study. BMC Ophthalmol. 2014; 14:47. PMC: 3984633. DOI: 10.1186/1471-2415-14-47. View

Qiao Q, Keinanen-Kiukaanniemi S, Laara E . The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol. 1997; 50(2):153-8. DOI: 10.1016/s0895-4356(96)00335-6. View

. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology. 1995; 102(4):647-61. DOI: 10.1016/s0161-6420(95)30973-6. View

10.

Turgut B, Gul F, Ilhan N, Demir T, Celiker U . Comparison of serum glycosylated hemoglobin levels in patients with diabetic cystoid macular edema with and without serous macular detachment. Indian J Ophthalmol. 2010; 58(5):381-4. PMC: 2992911. DOI: 10.4103/0301-4738.67044. View

11.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

12.

Asensio-Sanchez V, Gomez-Ramirez V, Morales-Gomez I, Rodriguez-Vaca I . [Clinically significant diabetic macular edema: systemic risk factors]. Arch Soc Esp Oftalmol. 2008; 83(3):173-6. View

13.

Berger V, Munk M, Lersch F, Wolf S, Ebneter A, Zinkernagel M . Association of Intravitreal Injections With Blood Pressure Increase: The Following Excitement and Anxiety Response Under Intravitreal Injection Study. JAMA Ophthalmol. 2018; 137(1):87-90. PMC: 6439777. DOI: 10.1001/jamaophthalmol.2018.4892. View

14.

Zarbin M . Anti-VEGF Agents and the Risk of Arteriothrombotic Events. Asia Pac J Ophthalmol (Phila). 2018; 7(1):63-67. DOI: 10.22608/APO.2017495. View

15.

Wong W, Chee C, Bhargava M, Chai C, Lin H, Zhao P . Systemic Factors Associated with Treatment Response in Diabetic Macular Edema. J Ophthalmol. 2020; 2020:1875860. PMC: 7125481. DOI: 10.1155/2020/1875860. View

16.

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

17.

. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care. 2016; 39(7):1089-100. PMC: 4915557. DOI: 10.2337/dc16-0024. View

18.

Acan D, Calan M, Er D, Arkan T, Kocak N, Bayraktar F . The prevalence and systemic risk factors of diabetic macular edema: a cross-sectional study from Turkey. BMC Ophthalmol. 2018; 18(1):91. PMC: 5897948. DOI: 10.1186/s12886-018-0753-y. View

19.

Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H . The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond). 2008; 23(8):1714-8. DOI: 10.1038/eye.2008.360. View

20.

Liu Z, Ma X, Liao D, Liu X, Bai L, Yao J . Association of urinary albumin excretion with central foveal thickness and intravitreal conbercept treatment frequency in patients with diabetic macular edema. Int J Ophthalmol. 2019; 12(10):1598-1604. PMC: 6796094. DOI: 10.18240/ijo.2019.10.12. View